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BACKGROUND: This phase I study assessed the maximum tolerated dose, dose-limiting toxicity (DLT) and pharmacokinetics of
belinostat with carboplatin and paclitaxel and the anti-tumour activity of the combination in solid tumours.
METHODS: Cohorts of three to six patients were treated with escalating doses of belinostat administered intravenously once daily,
days 1–5 q21 days; on day 3, carboplatin (area under the curve (AUC) 5) and/or paclitaxel (175mgm
 2) were administered 2–3h
after the end of the belinostat infusion.
RESULTS: In all 23 patients received 600–1000mgm
 2 per day of belinostat with carboplatin and/or paclitaxel. No DLT was observed.
The maximal administered dose of belinostat was 1000mgm
 2 per day for days 1–5, with paclitaxel (175mgm
 2) and carboplatin
AUC 5 administered on day 3. Grade III/IV adverse events were (n; %): leucopenia (5; 22%), neutropenia (7; 30%), thrombocytopenia
(3; 13%) anaemia (1; 4%), peripheral sensory neuropathy (2; 9%), fatigue (1; 4%), vomiting (1; 4%) and myalgia (1; 4%). The
pharmacokinetics of belinostat, paclitaxel and carboplatin were unaltered by the concurrent administration. There were two partial
responses (one rectal cancer and one pancreatic cancer). A third patient (mixed mullerian tumour of ovarian origin) showed a
complete CA-125 response. In addition, six patients showed a stable disease lasting X6 months.
CONCLUSION: The combination was well tolerated, with no evidence of pharmacokinetic interaction. Further evaluation of anti-tumour
activity is warranted.
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Aberrant gene transcription is one of the hallmarks of cancer.
Transcriptional regulation is controlled by an interaction of many
processes including histone tail modification (Grunstein, 1997).
The acetylation and deacetylation of histone tails is achieved by
competing the activity of histone acetyl transferases and histone
deacetylases (HDACs) (Grunstein, 1997). HDAC enzymes catalyse
the removal of acetyl groups from lysine residues of histone
proteins, compact chromatin and thus repress the transcription of
associated genes. Deregulation in the expression of HDAC
enzymes has been implicated in the development of cancers
(Marks et al, 2001), and as such, HDAC enzymes represent a
potential therapeutic target. HDAC inhibitors can induce apopto-
sis, cell cycle arrest and cellular differentiation, as well as inhibit
angiogenesis (Marks and Dokmanovic, 2005; Bolden et al, 2006b).
In addition, HDAC inhibitors have been shown to affect multiple
pathways involved in oncogenesis through acetylation of non-
histone proteins including heat shock protein-90, tubulin and
hypoxia-inducible factor-1a (Bolden et al, 2006b; Schemies et al,
2009). A variety of HDAC inhibitors have already shown some
anti-tumour activity in both pre-clinical and clinical settings
(Bolden et al, 2006b).
Belinostat (PXD101) is a low molecular weight HDAC inhibitor
of the hydroxamate class, having nanomolar activity against both
class I and II recombinant HDAC isoforms with the advantage
of both inducing histone acetylation and tubulin acetylation
(Khan et al, 2008). It shows growth-inhibitory effects in a variety of
human tumour cell lines in vitro, and human tumour xenografts
in vivo (Plumb et al, 2003). This in vitro and in vivo growth
inhibition was associated with a marked increase in the levels of
acetylated histone proteins (Plumb et al, 2003). In addition,
belinostat exhibited additive to synergistic when combined with
paclitaxel, docetaxel and carboplatin both in vitro and in vivo
(Qian et al, 2006), the postulated mechanism being through
belinostat enhancing the acetylation of tubulin induced by
docetaxel and phosphorylation of H2AX (variant of the histone
H2A family) induced by carboplatin.
In two phase I studies of belinostat in solid (Steele et al, 2008)
and haematological tumours (Gimsing et al, 2008), the treatment
was well tolerated at the maximum tolerated dose (MTD) of
1000mgm
 2 per day administered intravenously (i.v.), q21 days.
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sThe dose-limiting toxicities (DLT) in the solid tumour study
included fatigue, diarrhoea and atrial fibrillation, whereas none
were seen in the study of haematological tumours. Importantly, no
significant myelosuppression was observed.
On the basis of (i) the hypothesis that belinostat shows additive-
to-synergistic activity when combined with commonly used
cytototoxic agents including platinums (Pts) and taxanes and (ii)
the lack of overlapping toxicity with these agents, this phase I
study was designed to determine the MTD, DLT and the
pharmacokinetic (PK) profile of belinostat, carboplatin and
paclitaxel (BelCaP). Furthermore, it planned to explore the anti-
tumour activity of the combination in solid tumours and in an
MTD expansion of patients with relapsed advanced ovarian cancer.
MATERIALS AND METHODS
Eligibility
Patients with histological or cytological confirmation of advanced
solid malignancy refractory to standard therapy were eligible,
provided that they met the following criteria: age X18 years;
Eastern Co-operative Oncology Group performance status p2;
adequate bone marrow, hepatic and renal function (neutrophils
41.0 10
9l
 1, platelets 4100 10
9l
 1, total bilirubin
p1.5 upper limit of normal, aspartate aminotransferase, alanine
aminotransferase, alkaline phosphatase p3 upper limit of
normal (or p5 upper limit of normal if liver metastases) and
calculated creatinine clearance X45mlmin
 1); female patients
of reproductive potential were required to have a negative
pregnancy test.
Patients were excluded if they had co-existing significant
medical conditions including prolonged QTc 4500ms; use of
concomitant medication that may cause torsade de Pointes;
neuropathy Xgrade II because of previous treatment; or had
received 43 previous lines of chemotherapy for metastatic disease.
The study protocol was approved by the institutional ethics
committee of the three sites participating in the study and all
patients gave written informed consent before any study
procedures were performed. The study was conducted in line with
Good Clinical Practice in accordance with the Declaration of
Helsinki and its amendments.
Study design, objectives and treatment
This was an open-label phase I study with the primary objectives of
determining the safety, DLT and MTD of BelCaP. Secondary
objectives were to define the PK interaction between the agents as
well as define preliminary anti-tumour activity.
Belinostat was administered in escalating doses of 600, 800 and
1000mgm
 2 per day as a 30-min i.v. infusion on days 1–5 q21.
Carboplatin was administered as a 30-min i.v. infusion at area
under the curve (AUC) 5 on day 3 q21 days, whereas paclitaxel was
administered at 175mgm
 2 i.v. over 3h. Cytotoxics were given 2–
3h after the administration of belinostat–paclitaxel followed by
carboplatin. This schedule of belinostat followed by cytotoxics was
chosen on the basis of pre-clinical in vitro and in vivo data
supporting a higher degree of synergy, when HDAC inhibitors
were administered before topoisomerase II therapy (Marchion
et al, 2004, 2005). In addition, 48h pre-exposure with belinostat
was shown to be better than 24h, which was better than 12h.
Carboplatin was dosed in accordance with the Calvert formula
using ethylenediaminetetraacetic acid clearance to estimate glome-
rular filtration rate (GFR) (Calvert et al, 1989) at the European
Union sites and the Jelliffe formula at sites in the United States
(Jelliffe, 1973). Prophylactic anti-emetic and hypersensivity prophy-
laxis for paclitaxel were administered as per local standards.
A DLT was defined as an absolute neutrophil count
o0.5 10
9l
 1 lasting for X7 days, or absolute neutrophil count
o0.5 10
9l
 1 with sepsis; or platelet count o25 10
9l
 1.I n
addition, any other drug-related non-haematological grade III or
IV toxicity with the exceptions of alopecia, nausea and vomiting,
diarrhoea, rash, arthralgias and myalgias was categorized as DLT.
Treatment interventions were attempted to palliate toxicity
symptoms before concluding a DLT had occurred. The patients
who experienced DLT with documented clinical benefit (stable
disease (s.d.) or an objective response) were allowed to continue
treatment with BelCaP at the before dose level, if toxicity had
resolved to less than grade II (except for alopecia).
Dose escalation was planned in a classical 3þ3 design in up to
five cohorts. In cohort 1A, belinostat was to be administered
at 600mgm
 2 together with carboplatin AUC 5; in cohort 1B,
paclitaxel was to be evaluated with paclitaxel 175mgm
 2.
In cohort 2, belinostat at 600mgm
 2 was to be administered with
both carboplatin AUC 5 and paclitaxel at 175mgm
 2. In cohorts 3
and 4, belinostat was to be administered at 800 and 1000mgm
 2,
respectively, together with the same doses of BelCaP. Treatment
cycles were to be repeated until disease progression, evidence of
significant treatment-related toxicities, or withdrawal of consent.
Up to two dose reductions were to be allowed of all three drugs.
The patients who did not complete the first cycle were replaced.
Study assessments
Pre-treatment evaluation included history, physical examination,
laboratory assessments, chest x-ray, electrocardiogram (ECG),
urinalysis and tumour evaluation with computed tomography (CT)
or magnetic resonance imaging (MRI). Laboratory assessments
(complete blood count, clotting screen, urea, creatinine, electro-
lytes, liver function tests, uric acid, glucose and cholesterol) were
performed pre-treatment and weekly thereafter as well as on day 4
of cycles 1 and 2 only. Electrocardiograms were performed before
and within 1h after treatment with belinostat in cycle 1 and on
day 1 only of all subsequent cycles. Central ECG reading was
carried out using a digital analysis method.
Toxicities were graded according to the National Cancer
Institute Common Terminology Criteria for Adverse Events
version 3.0. Efficacy was assessed by CT or MRI performed every
two cycles using Response Evaluation Criteria in Solid Tumors
(RECIST) (Therasse et al, 2000).
Drug preparation
Belinostat was supplied by Topotarget as 10-ml vials, each
containing 50mgml
 1 belinostat and the solubilizer L-arginine
(100mgml
 1). Belinostat was stored below 51C. The assigned dose
of belinostat was added to a 250-ml bag of sterile sodium chloride
(0.9% solution or 5% dextrose solution) and immediately used.
Carboplatin and paclitaxel were prepared as indicated in the
summary of product characteristics for each agent.
Pharmacokinetic sampling and analysis
Blood samples for belinostat PK, when administered alone were
taken pre-treatment, at the end of infusion and 5min, 15, 30min,
1h, 2, 3h, 3h 15min, 3h 30min, 4, 5, 6h after infusion on days 1
and 3 of cycle 1. Samples for carboplatin or paclitaxel when
administered after belinostat, were taken relative to the start of
belinostat infusion at 3h (pre-carboplatin or-paclitaxel), 3h
15min, 3h 30min, 4, 5 and 6h in cycle 1 on day 3. In addition,
samples were taken for BelCaP when administered together at 6h
15min, 6h 30min, 7, 8, 9 and 24h after belinostat on day 3.
Belinostat and paclitaxel levels were determined in lithium-
heparinised plasma using validated solid-phase extraction high
performance liquid chromatograpgy (HPLC)-tandem mass spectro-
metric detection (MS/MS) methods (Covance, Indianapolis, IN, USA).
The lower limit of quantitation was 5 and 10ngml
 1 for belinostat and
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spaclitaxel, respectively. Belinostat plasma concentrations were deter-
mined at Covance using a validated method involving solid-phase
extraction, separation with acetic acid acetonitril gradient on reversed
phase C18 silica and MS/MS using penta-deuterated belinostat as the
internal standard. Belinostat and the internal standard were detected
using negative ion electron spray with the transition from 317 to 143
and 322 to 143mz
 1, respectively.
Paclitaxel and the internal standard, cephalomannine, are
extracted from human plasma by solid-phase extraction on a
cyanopropyl solid-phase extraction cartridge. After eluting with
the mobile phase, the eluent is directly analysed using liquid
chromatography with MS/MS. The standard curve range for this
assay is from 10.0 to 2000ngml
 1 for paclitaxel, using a plasma
sample volume of 0.250ml.
Human plasma samples were analysed for Pt from carboplatin
by inductively coupled plasma-mass spectrometry after dilution
with 0.01% Triton X-100 in 0.1% nitric acid. The samples were
analysed without pre-digestion or extraction directly against
matrix-matched standard solutions. Intensity, as counts per
second from Pt, mass 195, was measured. Terbium, mass 159,
was used as an internal standard. The results were calculated from
the net intensity ratio of Pt to internal standard. The standard
curve range was 2.00–1000ng Ptml
 1 in plasma. Samples above
the calibration range were diluted using blank human plasma.
Plasma concentration–time curves of all three analytes were
analysed by non-compartmental methods using WinNonlin
(version 4.0.1 Pharsight Corp., Cary, NC, USA). For all analytes
the AUC was estimated from the start of infusion by the
logarithmic-linear trapezoidal rule and extrapolated to infinity
using the estimated value of the slope of the terminal logarithmic-
linear disposition phase. Analysis was carried out on the non-dose-
normalised plasma concentration of carboplatin, as dosing had
already been normalised per GFR using Calvert’s formula (Calvert
et al, 1989).
RESULTS
Patient characteristics
In all 23 patients with a median age of 56 years (range 39–66) were
enroled between August 2005 and August 2006; the demographics
are described on Table 1. A total of 139 complete cycles were
administered (median 4; range 0–32; Table 2). A total of 10
patients completed X6 cycles of treatment.
Safety
All patients were evaluable for safety. Dose escalation proceeded
through all cohorts with no observed DLT attributable to the
combination of BelCaP. There were no grade IV non-haematolo-
gical adverse events (AE). Grade III AEs observed were peripheral
sensory neuropathy (n¼2), fatigue (n¼1), vomiting (n¼1) and
myalgia (n¼1) (Table 3). There was no cardiac toxicity; two events
of investigator-reported QTc prolongation in two patients were
later refuted by central ECG analysis. Grade III haematological AEs
comprised (n) leucopenia (5), neutropenia (3), thrombocytopenia
(3) and anaemia (1e) (Table 3). Three patients experienced grade
IV neutropenia. There was no evidence that the incidence of
haematological AEs increased with the addition of belinostat to
BelCaP. As per the protocol no further dose escalation beyond
1000mgm
 2 per day was attempted, and the recommended dose
was defined as belinostat (1000mgm
 2 per day) by 30-min i.v.
infusion once daily for 5 days every 21 days, with paclitaxel
(175mgm
 2) and carboplatin AUC 5 administered on day 3.
Pharmacokinetics
The belinostat pharmacokinetics was dose proportional at the dose
range evaluated (Table 4). In five of seven patients, the pre-
infusion values on day 3 were below the limit of quantitation,
Table 1 Patient characteristics
Characteristic No. of patients
Total 23
Age (years)
Median 56
Range 39–66
Sex
Male 14
Female 9
ECOG performance status
01 4
17
22
Previous anti-tumour regimens
01
18
24
37
43
Primary tumour type
Pancreatic carcinoma 3
Osteo/chondrosarcoma 3
Soft tissue sarcoma 2
Rectal carcinoma 2
Gastric carcinoma 2
Carcinoma of unknown primary 2
Ovarian carcinoma 2
Malignant melanoma 2
Mesothelioma 2
Bladder carcinoma 1
Hepatocellular carcinoma 1
Cholangiocarcinoma 1
Abbreviation: ECOG¼Eastern Co-operative Oncology Group.
Table 2 Dose escalation, exposure and dose-limiting toxicity
Cohort
Belinostat
day 1–5 (mgm
 2)
Carboplatin
day 3 (AUC
a)
Paclitaxel
day 3 (mgm
 2)
No. of
patients
b
Total no. of
completed cycles
Median no.
of completed
cycles (range)
Dose-limiting
toxicity
1A 600 5 — 5 25 4 (1–12) —
1B 600 — 175 5 40 6 (0–20) —
2 600 5 175 3 9 2 (1–6) —
3 800 5 175 4 36 2 (0–32) —
4 1000 5 175 6 29 5 (2–9) —
Abbreviations: AUC¼area under curve; EDTA¼ethylenediaminetetraacetic acid; GFR¼glomerular filtration rate.
aCalvert formula using chrome-EDTA clearance to estimate
GFR.
bPatients who did not complete the first cycle were replaced.
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sindicating that there was no accumulation of belinostat at the
1000mgm
 2 per day level. Administration of BelCaP on day 3 did
not alter the PK of belinostat. Similarly, there was no effect of
increasing the belinostat dose on the PK parameters of either
paclitaxel or carboplatin and these were comparable with that
reported in the literature (Tables 5 and 6) (Oguri et al, 1988; Bhalla
et al, 1999; Goffin et al, 2005).
Efficacy
In all 14 patients completed at least two cycles and were evaluable
for tumour response. Two patients showed a confirmed partial
response (PR), including one patient with metastatic pancreatic
cancer treated with belinostat and carboplatin and the other
patient with metastatic rectal cancer treated with belinostat with
BelCaP. The duration of response was 7 and 9 months,
respectively. Figure 1 shows the reduction in the size of adrenal
metastases in the patient with metastatic rectal carcinoma. These
patients had not previously received carboplatin or paclitaxel, but
the latter patient had received oxaliplatin. A third patient with a
mixed mullerian ovarian tumour, with radiologically s.d. by
RECIST, showed a complete CA-125 response. This patient had
previously received both BelCaP. A fourth patient with metastatic
transitional cell cancer of the bladder bones only, treated with
belinostat and paclitaxel, showed a resolution of a bony metastatic
deposit, but was otherwise rated s.d. by investigator. This patient
was previously treated with carboplatin and gemcitabine with a
best response of progressive disease.
Overall, eight patients showed a best response of s.d. (median
6.6 months; range 1–29); in seven of these eight patients s.d. lasted
X 6 months (range 6–29 months). These included patients with
metastatic transitional cell carcinoma (TCC) bladder, metastatic
cholangiocarcinoma, carcinoma of unknown primary (CUP),
ovarian cancer, rectal cancer, mesothelioma and Ewing sarcoma.
Five of these six patients had received Pt-based treatments
previously. Figure 2 shows a waterfall plot of the 14 patients
evaluable for response.
DISCUSSION
The safety and MTD of belinostat have been previously described
(Steele et al, 2008). We now present data from a phase I trial of a
Table 3 Non-haematological and haematological treatment related
adverse events
Cohort, n
Event or grade 1A 1B 2 3 4 Total (%)
Non-haematological
Nausea
1–2 2 3 1 3 4 13 (57)
3 0 0 000 0
Fatigue
1–2 1 4 1 2 3 11 (48)
3 0 0 010 1 ( 4 )
Vomiting
1–2 1 1 0 3 3 8 (35)
3 0 0 100 1 ( 4 )
Peripheral sensory neuropathy
1–2 0 3 0 1 2 6 (26)
3 0 0 110 2 ( 9 )
Alopecia
1–2 0 3 1 2 2 8 (35)
3 0 0 000 0
Flushing
1–2 2 3 0 2 1 8 (35)
3 0 0 000 0
Myalgia
1–2 0 3 1 1 2 7 (30)
3 0 0 100 1 ( 4 )
Arthralgia
1–2 0 3 1 1 1 6 (26)
3 0 0 000 0
Haematological
Anaemia
1–2 5 4 2 3 3 17 (96)
3 0 0 0 0 1 1 (13)
Leucopenia
1–2 2 4 1 3 2 12 (61)
3 0 0 0 3 2 5 (22)
Neutropenia
1–2 2 1 2 0 6 11 (65)
3 1 0 0 2 0 3 (13)
4 0 0 0 1 2 3 (13)
Thrombocytopenia
1–2 1 2 1 1 1 6 (48)
3 1 0 0 1 1 3 (13)
Table 4 Pharmacokinetic variables for belinostat (mean±s.d. for a single i.v. dose on days 1 and 3)
Belinostat dose
(mgm
 2)
No. of
patients T1/2 (h) Cmax (lM) AUCall (hlM) AUCinf (hlM)C l ( l h
 1m
 2) Vss (lm
 2)
600 12 1.7±0.9 58.5±13.8 28.4±7.1 28.4±7.1 69.7±15.2 34.9±6.4
800 4 1.7±0.2 70.8±18.9 35.5±8.7 35.6±8.7 73.7±14.1 38.1±9.7
1000 day 1 7 1.0±0.1 127.6±43.5 101.9±58.2 102.0±58.3 41.1±22.2 22.6±9.7
1000 day 3 7 2.7±0.4 134.7±54.9 88.8±63.9 88.8±63.9 45.1±17.3 35.8±17.3
Abbreviations: AUC¼area under curve; Cl¼clearance; i.v.¼intravenous; Vss¼steady state volumes of distribution.
Table 5 Pharmacokinetic variables for paclitaxel (mean±s.d. for a single i.v. dose of 175mgm
 2 on day 3 after belinostat administration)
Belinostat dose
(mgm
 2)
No. of
patients T1/2 (h) Cmax (lM) AUCall (hlM) AUCinf (hlM)C l ( l h
 1m
 2) Vss (lm
 2)
600 6 5.7±0.5 3.9±0.7 14.0±2.5 14.7±2.6 14.3±2.2 56.6±21.2
800 3 5.5±1.1 3.9±0.7 12.8±1.7 13.3±2.0 15.7±2.6 53.0±3.0
1000 7 5.5±0.6 3.9±1.3 14.4±3.8 15.0±4.0 14.8±4.9 57.2±31.7
Abbreviations: AUC¼area under curve; CV¼cardiovascular; i.v.¼intravenous.
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sfirst-in-man combination of the HDAC inhibitor with carboplatin
and/or paclitaxel, BelCaP. Carboplatin and paclitaxel were well
tolerated with no evidence of DLT up to the maximum
administered dose of 1000mgm
 2 per day belinostat with BelCaP
at standard doses. The most common toxicities were gastrointest-
inal and constitutional, often associated with BelCaP alone and
seen with single agent belinostat. However, there was no evidence
that the incidence or severity of these, or of haematological
toxicity, increased with the combination. It should be noted that
there was no evidence of significant cardiac toxicity, which has
been associated with HDAC inhibitors.
The toxicity profile of BelCaP was favourable and grade III/IV
neutropenia was reported in 26% of the patients and this was
probably attributed to BelCaP. Ramalingan et al reported that the
combination of the HDAC inhibitor vorinostat with BelCaP, resulted
in grade III/IV neutropenia in 50% of the patients, but in their study
t h ed o s eo fB e l C a Pw a sh i g h e rt h a ni n the present study (Ramalingam
et al, 2007a). Furthermore, when valproic acid was combined with
epirubicin, neurological DLTs were attributed to valproate with no
exacerbation of epirubicin-related myelosuppression (Munster et al,
2007). However, grade II–III QTc prolongation was seen in approxi-
mately 25% of patients in that study and as previously reported, this
was, in nearly all cases, associated with electrolyte abnormalities
(Munster et al, 2007; Piekarz et al, 2006).
PK results for belinostat showed that there was a dose-
proportional increase in belinostat exposure with increasing dose
and that there was no accumulation with repeat dosing. There
seemed to be no significant change in the PK parameters of
belinostat with the addition of BelCaP when compared with the PK
parameters seen in the single-agent phase I study (Steele et al, 2008).
The similarity between the PK parameters of BelCaP in this study
with historical controls, suggests that this combination is feasible,
although such a comparison with historical data has its limitations.
Encouragingly, BelCaP showed evidence of clinical activity in
heavily pre-treated patients, including those previously exposed
to Pt therapy. As a result of the clinical benefit in a patient
with metastatic TC of the bladder to bone, an expansion cohort
of BelCaP was initiated in patients with this tumour type.
Clinical efficacy has been observed with other combinations of
an HDAC inhibitor and cytotoxic chemotherapy. A total of 9 of 41
patients, with a variety of solid tumours, including prostate,
pancreatic, melanoma and cervical cancer, responded to valproic
acid with epirubicin; in a phase II portion of this study, 64% of
patients with breast cancer responded to treatment (Munster et al,
Table 6 Pharmacokinetic variables for Carboplatin equivalents
a (mean±s.d. for a single i.v. dose with target AUC 5 on day 3 after belinostat and paclitaxel
administration)
Belinostat dose
(mgm
 2)
No. of
patients
Carboplatin
dose (mgm
 2)
T1/2
(h)
Cmax
(lgml
 1)
AUCall
(mg.minml
 1)
AUCinf
(mg.minml
 1)
Cl
(lh
 1)
Vss
(l)
600 7 630.0±98.6 7.8±2.7 27.4±4.0 7.8±1.4 8.8±1.3 4.4±0.9 34.3±16.1
800 3 655.0±138.1 5.4±1.0 32.8±11.7 8.9±2.1 9.7±1.9 4.1±0.5 21.9±7.6
1000 7 537.1±105.4 6.0±0.8 29.6±14.0 8.4±1.0 9.3±1.1 3.5±0.8 20.4±3.5
Total Mean 596.2±113.4 6.6±2.1 29.2±1.0 8.2±1.4 9.2±1.3 3.9±0.8 26.4±12.5
%CV 19.0 31.0 34.1 17.0 14.2 21.4 47.3
Abbreviations: AUC¼area under curve; Cl¼clearance; CV¼cardiovascular; i.v.¼intravenous; Vss¼steady state volumes of distribution.
aTotal platinum measured was
converted to carboplatin equivalent by use of a 0.5254 conversion factor corresponding to ratio of formula weights; platinum 195.078gmol
 1 and carboplatin 371.3gmol
 1.
Figure 1 Efficacy of BelCaP in a patient with rectal cancer. Response in a patient with metastatic rectal carcinoma treated with BelCaP showing an adrenal
metastasis at baseline, (A) (encircled in red) measuring 7.7cm, and after six cycles, (B) measuring 3.6cm. The patient also had retroperitoneal lymph node
metastases and with this, showed a confirmed PR. (See online version for color information).
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Figure 2 Waterfall plot showing best response in individual patients
evaluable for responses assessment by RECIST 1.0 criteria. In all14 patients
completed the first two cycles and were evaluable for response and
featured in this plot. Dotted lines at þ20% and  30% indicate the % level
at which disease progression and disease response has occurred,
respectively.
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s2009). In the study of Ramalingam et al of 25 patients treated with
vorinostat and BelCaP, 10 patients with non-small-cell lung and 1
patient with head and neck cancer showed a PR (Ramalingam et al,
2007a). However, the majority of patients (82%) was chemotherapy
naive. The efficacy of this belinostat combination fares favourably
and merits further evaluation.
In summary, the combination of belinostat (100mgm
2 per day)
with carboplatin AUC5 and paclitaxel (175mgm
 2) is well
tolerated, with no evidence of any PK interaction. Recruitment
of patients to two expansion cohorts of ovarian cancer and TCC of
bladder has recently been completed and an evaluation in patients
with CUP is ongoing.
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